Product Information:

SALTRA 25+125 Inhaler is a combination pressurized metered-dose inhaler (pMDI) containing:

1. Salmeterol Xinafoate 25 mcg – a long-acting beta₂-agonist (LABA) that provides bronchodilation for up to 12 hours
2. Fluticasone Propionate 125 mcg – an inhaled corticosteroid (ICS) that reduces airway inflammation

This fixed-dose combination is used for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). It is not for acute symptom relief.

⚠️ Important Safety Note:

LABAs (like salmeterol) increase the risk of asthma-related death when used without an inhaled corticosteroid. This combination includes both, making it safe for maintenance—but never use salmeterol alone in asthma.

Uses of (SALTRA 25+125 INHALERS):

1. Maintenance treatment of moderate persistent asthma in patients not controlled on ICS alone
2. Symptom control and exacerbation reduction in COPD (FEV₁ <70% predicted)
3. Long-term management of wheezing, shortness of breath, chest tightness, and cough

Key Benefits of (SALTRA 25+125 INHALERS):

1. Dual action: anti-inflammatory (fluticasone) + long-acting bronchodilation (salmeterol)
2. Reduces frequency of asthma/COPD exacerbations
3. Improves lung function and quality of life
4. Once- or twice-daily dosing (typically 2 puffs twice daily)
5. HFA propellant—environmentally friendly (CFC-free)

How To Use (SALTRA 25+125 INHALERS):

1. Shake well before each use.
2. Prime before first use or if unused for >7 days (spray 4 test doses into the air).
3. Inhale technique:
4. Exhale fully (away from inhaler)
5. Place mouthpiece in mouth, seal lips
6. Press canister while inhaling deeply and slowly
7. Hold breath for 10 seconds, then exhale
8. Dosage:
9. Adults & adolescents (≥12 years): 2 puffs twice daily (morning and evening)
10. Rinse mouth with water after each use to prevent oral thrush.
11. Not for acute attacks—always carry a rescue inhaler (e.g., salbutamol).

When Not to Use (SALTRA 25+125 INHALERS):

Do not use if you have:

1. Hypersensitivity to salmeterol, fluticasone, or any excipients
2. Acute asthma attack or status asthmaticus
3. Primary treatment of status asthmaticus or acute COPD exacerbation

Side Effects of (SALTRA 25+125 INHALERS):

Common: Headache, throat irritation, hoarseness, oral candidiasis (thrush), cough.

Less common: Palpitations, tremor (from salmeterol), bruising (from fluticasone).

Serious (rare):

1. Adrenal suppression (with long-term high doses)
2. Reduced bone mineral density
3. Glaucoma or cataracts (with prolonged use)
4. Paradoxical bronchospasm (stop use if breathing worsens)
5. Rinse mouth after use to reduce local side effects.

Dosage: (SALTRA 25+125 INHALERS):

1. Adults & adolescents ≥12 years: 2 puffs twice daily
2. Maximum daily dose: 4 puffs (25/125 mcg x 4 = 100/500 mcg/day)
3. Not for children <12 years unless specifically directed
4. Do not stop abruptly—taper under medical supervision

Who It’s For (SALTRA 25+125 INHALERS):

1. Asthma patients requiring step-up therapy beyond low-dose ICS
2. COPD patients with frequent symptoms or exacerbations
3. Those needing combined anti-inflammatory and bronchodilator maintenance therapy

Warnings & Precautions:

1. Not a rescue inhaler—use salbutamol for acute symptoms
2. Monitor growth in adolescents on long-term therapy
3. Use caution in patients with active tuberculosis, ocular herpes, or osteoporosis
4. Transfer from oral steroids must be gradual and supervised

Drug Interactions:

1. Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): May increase systemic corticosteroid levels
2. Beta-blockers: May antagonize salmeterol and induce bronchospasm
3. Always inform your doctor about all medications.

Additional Information:

1. Each inhaler contains 120 actuations
2. Store below 30°C; do not puncture or expose to heat
3. Keep out of reach of children
4. Available by prescription in Pakistan